Martha Gulati: Oral MHT Is Associated With Increased Thrombotic Risk
Martha Gulati, Director of the Davis Women Heart Center at Houston Methodist DeBakey Heart and Vascular Center, shared The BMJ‘s post on X:
“Consistent with prior research, oral MHT is associated with increased thrombotic risk.
The same is not seen with transdermal MHT.”
The BMJ (British Medical Journal) shared a post on X about a recent article by Julie Berggreen et al., adding:
“Compared with no use of hormone therapy, oral menopausal hormone therapy was associated with increased venous thromboembolic risk regardless of dosage and treatment duration, finds study.
No increased thrombotic risks were observed with transdermal therapy.”
Title: Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study
Authors: Julie Berggreen, Nelsan Pourhadi, Hannah Wood-Kurland, Ellen Løkkegaard, Christian Torp-Pedersen, Amani Meaidi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 1, 2026, 23:44Priya Sriskandarajah: HEMA-MED Trial Exploring Roginolisib Plus JAK Inhibitors in Myelofibrosis
-
Oct 1, 2026, 23:44Inge Vanhomwegen: Join Our Upcoming Webinar on D-dimer Testing
-
Oct 1, 2026, 23:43Bianca Rocca: Beyond API-CAT – Who Should Continue Anticoagulation, And for How Long?
-
Oct 1, 2026, 23:26Sara Gaafar Ibnauf Suliman: The Changing Role of Bariatric Surgery in the GLP-1 Era
-
Oct 1, 2026, 23:16Ahmed Reda: New Ferritin Cutoffs For Iron Deficiency – Ash 2026
-
Oct 1, 2026, 23:04Mario Ottiglio: Launching New Initiative During UNGA81 Week through WCSCD
-
Oct 1, 2026, 22:56Suvro Sankha Datta: Can Blood Group Genotyping Help in Distinguishing between the Aweak and Ah with Similar Serological Results
-
Oct 1, 2026, 22:50Ifeanyichukwu Ifechidere: D-dimer – Why is This Test Being Ordered – and What is It Actually Telling You?
-
Oct 1, 2026, 15:44A Century of Von Willebrand Disease Awareness – EHC